BMS to invest in, collaborate with Compugen

Oct 12, 2018

Bristol-Myers Squibb and Israel-based Compugen said they will collaborate in clinical trials for patients with advanced solid tumors.

The trials will evaluate the safety and tolerability of Compugen’s COM701, an investigational antibody, in combination with BMS’ immune checkpoint inhibitor, Opdivo.

Additionally, Bristol-Myers Squibb will invest $12 million in Compugen, purchasing 2,424,243 shares — a 4.1 percent stake.

Read the press release

Don't miss your Daily Dose! Subscribe to the daily eNewsletter

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments